Anti-CD4 antibody
View Patent ↗An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.
1. A monoclonal antibody or antibody fragment thereof, wherein
said monoclonal antibody competes for binding to an extracellular region of CD4 with, and/or blinds to the same epitope in an extracellular regions of CD4 as, a reference antibody,
wherein said reference antibody comprises a heavy chain (H chain) and a light chain (L chain),
wherein complementarity determining regions (CDRs) 1 to 3 of said H chain comprise the amino acid sequences of SEQ ID NOs:51 to 53, respectively, and wherein CDRs 1 to 3 of said L chain comprise the amino acid sequences of SEQ ID NOs:54 to 56, respectively.
2. A monoclonal antibody or antibody fragment thereof, wherein
said monoclonal antibody competes for binding to an extracellular region of CD4 with, and/or binds to the same epitope in an extracellular region of CD4 as, a reference antibody,
wherein said reference antibody comprises a heavy chain (H chain) and a light chain (L chain),
wherein CDRs 1 to 3 of said H chain comprise the amino acid sequences of SEQ ID NOs:27 to 29, respectively, and wherein CDRs 1 to 3 of said L chain comprise the amino acid sequences of SEQ ID NOs:30 to 32, respectively.
3. A monoclonal antibody or antibody fragment thereof selected from the group consisting of (a) and (b):
(a) a monoclonal antibody or antibody fragment thereof comprising an H chain variable region (VH) and an L chain variable region (VL), wherein said VH and VL comprise the amino acid sequences of SEQ ID NOs:16 and 26, respectively, or wherein said VH and VL comprise the amino acid sequences of SEQ ID NOs:12 and 22, respectively; and
(b) a monoclonal antibody or antibody fragment thereof comprising a heavy chain (H chain) and a light chain (L chain), selected from the group consisting of (i) and (ii):
a monoclonal antibody or antibody fragment thereof in which CDRs 1 to 3 of said H chain comprise the amino acid sequences of SEQ ID NOs:51 to 53, respectively, and CDRs 1 to 3 of said L chain comprise the amino acid sequences of SEQ ID NOs:54 to 56, respectively, and;
(ii) a monoclonal antibody or antibody fragment thereof in which CDRs 1 to 3 of said H chain comprise the amino acid sequences of SEQ ID NOs:27 to 29, respectively, and CDRs 1 to 3 of said L chain comprise the amino acid sequences of SEQ ID NOs:30 to 32, respectively.
4. A monoclonal antibody or antibody fragment thereof, wherein said monoclonal antibody or antibody fragment thereof comprises an H chain variable region (VH) and an L chain variable region (VL), and wherein said monoclonal antibody or antibody fragment thereof is selected from the group consisting of (a)-(e):
(a) a humanized antibody in which said VH and VL comprise the amino acid sequences of SEQ ID NOs:77 and 78, respectively;
(b) a humanized antibody in which said VH and VL comprise the amino acid sequences of SEQ ID NOs:96 and 78, respectively;
(c) a humanized antibody in which said VH and VL comprise the amino acid sequences of SEQ ID NOs:98 and 78, respectively;
(d) a humanized antibody in which said VH and VL comprise the amino acid sequences of SEQ ID NOs:100 and 78, respectively; and
(e) a humanized antibody in which said VH and VL comprise the amino acid sequences of SEQ ID NOs:100 and 102, respectively.
5. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 , 2 , 3 , and 4 , wherein the dissociation constant (K D ) for the antibody-antigen interaction of said monoclonal antibody or antibody fragment thereof is less than 1×10 −9 M, and wherein said monoclonal antibody or antibody fragment thereof exhibits high antibody-dependent cellular cytotoxicity (ADCC).
6. The monoclonal antibody or antibody fragment thereof according to claim 5 , wherein said monoclonal or antibody fragment thereof exhibits high complement-dependent cellular cytotoxicity (CDC activity).
7. The monoclonal antibody or antibody fragment thereof according to claim 6 , wherein said monoclonal antibody or antibody fragment exhibits CDC activity against a human cancer cell line expressing human CD4.
8. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 , 2 , 3 and 4 , wherein the monoclonal antibody is a recombinant antibody.
9. The monoclonal antibody or antibody fragment thereof according to claim 8 , wherein the recombinant antibody is a recombinant antibody selected from the group consisting of a human chimeric antibody, a humanized antibody and a human antibody.
10. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 , 2 , 3 and 4 , wherein said antibody fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 , a single chain antibody (scFv), a dimerized V region (diabody), a disulfide stabilized V region (dsFv), and a peptide comprising CDR.
11. A pharmaceutical composition comprising the monoclonal antibody or antibody fragment thereof according to any one of claims 1 , 2 , 3 , and 4 , and a pharmaceutically acceptable carrier.